Skip to main content
Caplight Logo









Expora Therapeutics

Expora Therapeutics

Private
College Park, MarylandHealthcare & Life Scienceshttps://exporatx.com/

Last Round

Grant

Dec 1, 2025

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Expora Therapeutics is a biotechnology company that develops oral bacterial extracellular vesicle disease-modifying immunotherapies for gastrointestinal diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

bacterial extracellular vesiclesBEVbiomanufacturinggut-restricted immunotherapyGMP manufacturingsynthetic biologydrug delivery platformCDMOgastrointestinal therapeuticsbioactive cargo deliverymicrobiome therapeuticsnext-gen probioticsbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Expora Therapeutics Comparables

Compare Expora Therapeutics with similar companies based on industry and business-model similarity.

Expora Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MD Healthcare
68%
Delonix Bioworks
63%
Evox Therapeutics
61%

Expora Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 1, 2025
GrantFeb 1, 2025

Expora Therapeutics Investors

Notable investors and investment history

Expora Therapeutics investors
InvestorRounds
University System of Maryland Launch FundGrant
TEDCOGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors increased 251% MoM, from 93 to 326.

  • Dec 1, 2025

    Received funding from the University System of Maryland Launch Fund.

Expora Therapeutics Filings

Explore SEC and related filing metadata, where available.

Expora Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Expora Therapeutics's valuation, stock price, and market status.

Is Expora Therapeutics a public or private company?

Expora Therapeutics is a private company.

What is the current stock price of Expora Therapeutics?

Expora Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Expora Therapeutics worth (valuation)?

Valuation information for Expora Therapeutics is not publicly available.

Can I buy Expora Therapeutics stock?

Expora Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Expora Therapeutics's last funding round?

Funding round information for Expora Therapeutics is not publicly available.

Who are the main investors in Expora Therapeutics?

Investor information for Expora Therapeutics is not publicly disclosed.

Will Expora Therapeutics IPO soon?

No public IPO plans have been announced for Expora Therapeutics.

How can I track Expora Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Expora Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCollege Park, Maryland
Employee Range2
Year Founded2025
Last FundingDec 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?